Key result
Quinidine and sotalol show individual-dependent antiarrhythmic effects in Brugada syndrome iPSC-CM models.
Why the study?
SCN5A genotype-phenotype correlations in Brugada syndrome are not completely matched, with clinical phenotypes of a single variant ranging from asymptomatic to sudden cardiac death.
Population
26 iPSC lines from a SCN5A mutation-positive (D356Y) BrS family and healthy controls
Comparison
Severely affected proband vs asymptomatic mutation carriers vs healthy controls
Design
In vitro patient-specific iPSC-derived cardiomyocyte disease-modeling study
Authors
Loading...
Hypothesis-generating for individualized Brugada therapy; leaves open clinical translation of iPSC-CM screening.
Patient-specific iPSC-CMs reveal variable phenotypic severity in Brugada syndrome and demonstrate individual-dependent responses to antiarrhythmic drugs.
Sun et al. (2023) studied Brugada syndrome. Drug screening (quinidine, sotalol) and calcium administration vs. Healthy controls and asymptomatic mutation carriers was evaluated on Antiarrhythmic effects and arrhythmic events. Drug screening using established Brugada syndrome iPSC-CM models demonstrated that quinidine and sotalol possessed antiarrhythmic effects in an individual-dependent manner.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: